Blood Pressure and Vascular Effects of Leptin in Humans by Brook, Robert D. et al.
METABOLIC SYNDROME AND RELATED DISORDERS
Volume 5, Number 3, 2007
© Mary Ann Liebert, Inc.
Pp. 270–274
DOI: 10.1089/met.2006.0023
Blood Pressure and Vascular Effects of 
Leptin in Humans
ROBERT D BROOK M.D.,1 ROBERT L BARD M.A.,1 PETER F BODARY Ph.D.,1
DANIEL T EITZMAN M.D.,2 SANJAY RAJAGOPALAN M.D.,3 YAN SUN M.S.,3
and ALEX M DEPAOLI M.D.1
ABSTRACT
Background: Leptin may play a role in mediating obesity-related hypertension. However, its
effects on the vasculature and blood pressure (BP) remain poorly defined in humans.
Methods: In the first study, we performed a short-term, placebo-controlled, randomized,
double-blind, cross-over experiment investigating the actions of recombinant human leptin
(r-metHuLeptin) in 15 nonobese adults. To compliment the acute study, we retrospectively
analyzed available BP results from a previously performed 85–day, placebo-controlled, ran-
domized, double-blind, parallel weight-loss study using r-metHuLeptin in 284 obese adults.
Results: In the acute study, conduit artery endothelial function determined by brachial flow-
mediated dilatation (FMD) increased 2 hours following 0.2 mg · Kg1 subcutaneously (SC) of
r-metHuLeptin versus placebo (3.3% versus 2.8%, P  .02). BP remained unchanged 4 hours
after injections. In the retrospective analysis of the weight loss study data, 10 mg every day
before noon (QAM), 10 mg every day after noon (QPM), or 10 mg twice a day (BID) SC of 
r-metHuLeptin was found to not alter the degree of weight loss (3.2  3.7 versus 2.9  3.2
Kg, P  .54), change in systolic (1.6  12.9 versus 2.0  13.9 mmHg, P  .85) and diastolic
BP (0.2  8.7 versus 1.5  8.6, P  .30), as well as heart rate (1.4  10.7 versus 1.4 
10.4 beats/min, P  .98) compared to placebo.
Conclusions: In our acute study, marked hyperleptinemia rapidly enhanced endothelial
function and did not alter BP. The available data from a longer-term study in healthy obese
adults did not demonstrate a significant effect of hyperleptinemia upon BP. These combined
findings do not support a direct role for leptin in linking obesity to hypertension, however
more studies are required to corroborate these observations. 
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INTRODUCTION
HYPERLEPTINEMIA MAY BE A MECHANISM link-ing obesity with hypertension.1,2 Leptin is
secreted by adipocytes and modulates sympa-
thetic nervous system activity to regulate body
weight. Therefore, a potential consequence of
hyperleptinemia may be elevated arterial blood
pressure (BP). These autonomic actions are
countered by direct leptin-mediated vasodi-
latation.3 “Selective tissue resistance” to leptin
may promote chronic hypertension in human
obesity if its pressor actions remain sensitive
while the vasodilatory responses are blunted.
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2,4 Indeed, several animal experiments have
demonstrated that leptin sub-acutely causes a
net increase in BP.4,5 Leptin’s hemodynamic ac-
tions remain incompletely described in hu-
mans, therefore the aim of this study was to in-
vestigate the direct effect of leptin on BP and
vascular function in healthy adults.
METHODS
Two separate experiments following use 
of recombinant methionyl human leptin (r-
metHuLeptin) (Amgen Inc, Thousand Oaks, CA)
were performed. The acute study was prospec-
tively performed at the University of Michigan
and approved by its Institutional Review Board.
Fifteen healthy nonsmoking adults with a body
mass index (BMI)  27 kg · m2 and without car-
diovascular risk factors signed informed consent
and were enrolled. None of the participants were
taking any medication known to alter BP or en-
dothelial function. Subjects entered into a ran-
domized, double-blind, cross-over study (2 week
washout) of r-metHuLeptin 0.2 mg · kg1 SC ver-
sus placebo (sorbitol and sodium acetate, pH 4.0,
of the same volume). Subjects fasted more than
8 hours overnight, had brachial artery flow me-
diated dilatation (FMD) performed,6 and had
blood drawn before and 2 and 4 hours after in-
jections. Three seated BP values in the dominant
arm were measured (Omron 711AC, Omron
Healthcare, Inc., Bannockburn, IL). and averaged
at the start and at the 4 hour time point. 
As far as we are aware, there have been no pub-
lished data on the long-term effects of leptin on
BP in humans. In order to complement the results
of the acute study findings, to gain insight into
the more biologically important long-term ac-
tions of leptin, we obtained permission from the
investigative team (A.M.D., Amgen Inc, Thou-
sand Oaks, CA) to analyze the BP results (which
had not been published) from a previously per-
formed weight loss study. This chronic study was
conducted in obese subjects from September 1997
to August 1998 at 8 clinics in the Netherlands,
Sweden, and the United Kingdom. Subjects were
otherwise healthy adults, with the exception of
obesity. Those with comorbidities such as drug-
treated diabetes, hyperlipidemia, and uncon-
trolled hypertension were excluded. All subjects
provided written informed consent, and an in-
dependent Ethics Committee at each study site
approved the protocol. Subjects were randomly
assigned in a 1:1:1 allocation to 3 different treat-
ment regimens of r-metHuLeptin or matching
placebo allocated 3:1 (active drug:placebo) within
each regimen (10 mg subcutaneously [SC] daily
before noon [QAM], or 10 mg SC daily after noon
[QPM], or 10 mg SC twice a day [BID]). Obese
subjects with a BMI between 27.5 and 37.0 kg ·
m2 were enrolled in a 3–week dietary lead-in
phase in which subjects were prescribed a 2100
kJ · day1 (500 kcal · day2) deficit diet. All sub-
jects received single-blinded placebo injections
throughout the dietary lead-in phase. Only sub-
jects with a weight loss between 0 and 5.0 kg and
a BMI over 25.0 kg · m2 were eligible to con-
tinue into the treatment phase. Subjects were then
randomized into the 3 treatment regimens in a
stratified fashion according to body weight loss
during the dietary lead-in (2.0 kg or 2.0 kg).
Drug or placebo was self administered SC dur-
ing the study. Fasting BP was measured in the
morning (7–9 am) at the start and end of the treat-
ment phase by standardized methods across
sites. Subjects rested in a sitting position for 5
minutes and a single BP was measured by aus-
culatation using appropriate-sized arm cuffs and
resting heart rate was determined. Blood was
then drawn for fasting plasma leptin levels.
In our acute study, BP responses were com-
pared by paired t-test. FMD values at the 0, 2,
TABLE 1. PATIENT CHARACTERISTICS ENROLLED
IN THE ACUTE STUDY
Mean  SD
(n  14)
Age (years) 26  70
Male/Female (no.) 6/9
Body Weight (kg) 70  16
Systolic Blood Pressure (mm Hg) 112  120
Diastolic Blood Pressure (mm Hg) 66  80
Total Cholesterol (mg · dL1) 157  320
High Density Lipoprotein (mg · dL1) 60  15
Low Density Lipoprotein (mg · dL1) 78  25









and 4 hour time points were compared by a
mixed effects model adjusted for effects of se-
quence, period, treatment, and time. Change in
plasma leptin was correlated to the change in
FMD by Pearson correlation coefficient. In the
retrospective analysis of the previously per-
formed chronic study, the data on file were ob-
tained from the company and weight loss and
BP changes were compared by independent
samples t-tests. Values are expressed as mean
/ SD and significance was defined as P.05
for all tests.
RESULTS
The characteristics of the patients in the 
acute study are shown in Table 1. There were
no significant changes in BP 4 hours after 
r-metHuLeptin injection compared to placebo
(Table 2). Data on 1 patient were lost and 
not included. Figure 1 demonstrates that
brachial FMD was significantly enhanced by 
r-metHuLeptin after 2 hours and trended to-
wards an increase at 4 hours. Mean plasma lep-
tin concentrations increased from a normal
baseline value of 9.0  6.8 to 135  39.3 ng ·
mL1 2 hours after r-metHuLeptin injection.
The increase in leptin (mean  126.4 ng · mL1)
correlated to the change in brachial FMD at 2
hours (r0.52, P.059).
Table 3 shows the baseline characteristics of
the patients that were previously enrolled in
the long-term weight loss study. There were no
changes in basal brachial artery diameter after
leptin. The reductions in weight, BP and heart
rate did not differ significantly between groups
(Table 4). Baseline mean plasma leptin was the
same for each group (19  14 ng · mL1), how-
ever, levels at day 85 were higher in the r-
TABLE 2. BLOOD PRESSURE RESPONSES IN THE ACUTE STUDY, N  14, ALL P  .05
Treatment Baseline 4 hour
Placebo Systolic Blood Pressure (mm Hg) 112  10 112  10
Diastolic Blood Pressure (mm Hg) 66  7 66  9
r-metHul Systolic Blood Pressure (mm Hg) 113  13 115  14
Diastolic Blood Pressure (mm Hg) 66  9 65  10
BP was measured only at the 4 hour time point post injections
FIG. 1. Acute mean changes in brachial flow mediated dilatation in response to r-metHuLeptin versus placebo.
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metHuLeptin (448  474 ng · mL1) versus the
placebo group (18  13 ng · mL1).
DISCUSSION
Leptin may play a role in obesity-related hy-
pertension and alter vascular function.4,5 Few
data exist on the BP and vascular actions of lep-
tin in humans to confirm this hypothesis. We
have made one of the first attempts to address
the relevance of this mechanistic pathway in
humans by examining both the acute and
chronic actions of exogenous leptin. Within
hours, an increased plasma leptin level en-
hanced endothelial function (brachial FMD) in
nonobese adults and did not alter BP. From the
data that is available from a previously per-
formed study, marked chronic hyperleptine-
mia also did not appear to affect BP or heart
rate in obese adults.
It has been hypothesized that selective lep-
tin resistance, in the presence of chronic hy-
perleptinemia due to obesity, could promote
hypertension.2 However, there is no direct ev-
idence to support this hypothesis in humans.
Cross-sectional studies linking BP, obesity, and
leptin levels cannot discern physiologically-
causal roles from “innocent” associations. In-
tervention trials of exogenous leptin thus pro-
vide unique opportunities to directly address
whether leptin per se plays a causal role in al-
tering hemodynamics in humans.  Our findings
corroborate 2 prior experiments, which re-
ported that leptin acutely enhances vasodila-
tory pathways in humans without altering BP
over hours.7,8 Our current study is the first ex-
periment to demonstrate that leptin enhances
TABLE 3. BASELINE DEMOGRAPHICS OF PATIENTS IN THE CHRONIC STUDY
Placebo r-metHuL
10mg (am) 10mg (pm) 10 mg BID 10mg (am) 10mg (pm) 10mgBID Total
(n  25) (n  24) (n  24) (n  70) (n  70) (n  71) (n  284)
Age (yrs) Mean 43.9  9.9 49.5  8.6 44.9  10.8 47.0  9.9 47.1  11.1 47.0  10.9 46.8  10.4
Male No. (%) 8 (32%) 9 (38%) 6 (25%) 28 (40%) 22 (31%) 23 (32%) 96 (34%)
Female No. (%) 17 (68%) 15 (63%) 18 (75%) 42 (60%) 48 (69%) 48 (68%) 188 (66%)
Weight (kg) Mean 94.7  15.3 94.6  11.1 91.1  12.8 94.0  13.0 92.6  12.2 90.8  12.2 92.7  12.6
BMI Mean 32.7  2.9 32.7  2.1 31.7  2.8 32.2  2.2 32.3  2.4 31.9  2.7 32.2  2.5
Weight loss No. (%) 11 (44%) 10 (41.7%) 10 (41.7%) 31 (44.3%) 30 (42.9%) 31 (43.7%) 123 (43.3%)
2kg*
Weight loss No. (%) 14 (56%) 14 (58.3%) 14 (58.3%) 39 (55.7%) 40 (57.1%) 40 (56.3%) 161 (56.7%)
	2 kg 2 kg* 
Values are mean  SD.
*Summarized based on levels of the randomization stratification factor during dietary weight loss period
TABLE 4. WEIGHT AND BLOOD PRESSURE RESPONSES TO CHRONIC TREATMENTS
Baseline Change at Day 85
r-metHuLeptin Placebo r-metHuLeptin Placebo P
Weight (kg) 92.6  12.4 93.5  13.1 3.2  3.7 2.9  3.2 .54
(n  208) (n  73) (n  189) (n  68)
SBP (mm Hg) 126.1  15.6 128.6  14.3 1.6  12.9 2.0  13.9 .85
(n  208) (n  72) (n  187) (n  67)
DBP (mm Hg) 77.2  9.5 78.5  8.9 0.2  8.7 1.5  8.6 .30
(n  208) (n  72) (n  187) (n  67)
HR (beats · min1) 69.9  9.8 69.8  11.0 1.4  10.7 1.4  10.4 .98
(n  204) (n  73) (n  180) (n  66)
Values are mean  SD. Leptin group represents mean responses of all patients placed upon r-metHuLeptin at all
doses.
P  2 samples t-test comparing day 85 changes between r-metHuLeptin and placebo groups
n  number of patients where measurement was made per group
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“endothelial function” as assessed by the stan-
dardized brachial FMD protocol. Moreover, the
more relevant long-term hemodynamic actions
of leptin have not been previously reported. In
this analysis of the data from a previous
chronic study, high dose r-metHuLeptin pro-
duced extreme hyperleptinemia, but did not
significantly increase BP or heart rate com-
pared to control patients with the same mod-
est amount of weight loss. If high physiologic
levels of leptin were contributing to elevated
BP in humans, it would be expected that ex-
ogenous leptin would produce even further el-
evations in BP, or at the very least blunt the hy-
potensive effect of the observed weight loss.
This lack of a prohypertensive action of phar-
macologically-induced chronic extreme hyper-
leptinemia, coupled with the confirmation that
leptin acutely enhances endothelial function
without altering BP, does not support the hy-
pothesis that leptin per se directly plays a
causal role in elevating BP in humans.
We recognize that our findings are the first at-
tempt to specifically investigate both the acute
and chronic effects of leptin on BP in humans.
Therefore, there are several limitations in our
studies that require these observations to be cor-
roborated by future studies prior to making any
definitive statement about the existence or
nonexistence of a prohypertensive action of lep-
tin. We cannot discount that the exogenous
source of leptin and nonphysiologic plasma ki-
netics and marked plasma concentrations may
not represent human (patho)physiology and
may have contributed to our null findings. Since
the weight loss in the leptin limb was not statis-
tically greater than placebo, it is possible that the
physiological actions of leptin were blunted in
these patients (i.e., nonselective resistance). This
may have contributed to a lack of a potential pro-
hypertensive action. However, the particular ad-
vantages of these data are that they demonstrate
that for equal degrees of weight loss, marked hy-
perleptinemia per se does not directly elevate BP.
Finally, both studies were not specifically de-
signed to detect small treatment differences in
BP change. Larger studies using more sensitive
techniques may uncover smaller effects missed
in our studies (type 2 errors). However, even if
a small effect were uncovered, it would not be
consistent with leptin playing a major role in me-
diating obesity-related hypertension.
In summary, acute elevations in plasma lep-
tin rapidly enhance conduit endothelial func-
tion as assessed by brachial FMD. We did not
demonstrate that acute or chronic hyper-
leptinemia raises BP in healthy humans. More
in-depth studies to confirm or refute a role for
leptin in mediating obesity-hypertension in
both lean and obese humans are clearly war-
ranted based upon our initial findings.
ACKNOWLEDGEMENT
This study was funded by the General Clin-
ical Research Center at the University of Michi-
gan (MO1–RR00042) and Amgen Incorporated.
REFERENCES
1. Grassi G. Leptin, sympathetic nervous system, and
baroreflex function. Curr Hypertens Rep 2004;6:236–240.
2. Mark AL, Correia MLG, Rahmouni K, Haynes WG. Se-
lective leptin resistance: a new concept in leptin phys-
iology with cardiovascular implications. J Hypertens
2002;20:1245–1250.
3. Ren J. Leptin and hyperleptinemia – from friend to foe
for cardiovascular function. J Endocrin 2004; 181: 1–10.
4. Rahmouni K, Morgan DA, Morgan GM, Mark AL,
Haynes WG. Role of selective leptin resistance in diet-in-
duced obesity hypertension. Diabetes 2005;54:2012–2018.
5. Carlyle M, Jones OB, Kuo JJ, Hall JE. Chronic cardio-
vascular and renal actions of leptin. Role of adrenergic
activity. Hypertension 2002;39:496–501.
6. Rajagopalan S, Brook RD, Rubenfire M, Pitt E, Young
E, Pitt B. Abnormal brachial artery flow-mediated va-
sodilatation in young adults with major depression.
Am J Cardiol 2001;88:196–198.
7. Nakagawa K, Higashi Y, Sasaki S, Oshima T, Matsuura
H, Chayama K. Leptin causes vasodilation in humans.
Hypertens Res 2002;25:161–165.
8. Matsuda K, Teragawa H, Fukuda Y, Nakagawa K, Hi-
gashi Y, Chayama K. Leptin causes nitric-oxide inde-
pendent coronary artery vasodilation in humans. Hy-
pertens Res 2003;26:147–152.
Address reprint requests to:
Robert D Brook MD
24 Frank Lloyd Wright Dr.
P.O. Box 322
Ann Arbor, MI, 48106–0739
E-mail: robdbrok@umich.edu
This article has been cited by:
1. Yolanda E Bogaert, Stuart Linas. 2009. The role of obesity in the pathogenesis of hypertension. Nature Clinical Practice Nephrology
5:2, 101-111. [CrossRef]
